Emergence of Inflammatory Bowel Disease During Treatment With Secukinumab

Secukinumab is an anti-IL 17A monoclonal antibody currently licensed for the treatment of plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. However, although inflammatory bowel disease is a disorder with related immune characteristics, secukinumab has not proved to be effective in t...

Full description

Saved in:
Bibliographic Details
Published in:Journal of Crohn's and colitis 2018-08, Vol.12 (9), p.1131-1133
Main Authors: Fobelo Lozano, María José, Serrano Giménez, Reyes, Castro Fernández, Manuel
Format: Article
Language:English
Subjects:
Antibodies, Monoclonal, Humanized - adverse effects
Female
Humans
Inflammatory Bowel Diseases - chemically induced
Inflammatory Bowel Diseases - diagnosis
Male
Middle Aged
Psoriasis - drug therapy
Young Adult
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Secukinumab is an anti-IL 17A monoclonal antibody currently licensed for the treatment of plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. However, although inflammatory bowel disease is a disorder with related immune characteristics, secukinumab has not proved to be effective in these diseases. In fact, negative results in a clinical trial designed to assess the efficacy of secukinumab in patients with Crohn's disease have been published. On the other hand, the drug fact sheet states that secukinumab should be used with caution in patients with inflammatory bowel disease. Although the drug has shown to worsen these pathologies, there are no published data of cases in which the patient is first diagnosed with inflammatory bowel disease during secukinumab treatment. We present two cases of emergence of inflammatory bowel disease in patients with plaque psoriasis and ankylosing spondylitis, treated with secukinumab.
ISSN:1873-9946
1876-4479
DOI:10.1093/ecco-jcc/jjy063